18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal document ...

GSK’s follow-up to severe asthma therapy Nucala, depemokimab, clears two phase 3 trials, reducing attacks compared to placebo with six-monthly dosing.